$CNTX insiders have traded $CNTX stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. We have seen 8 ...
CNTX stock is down over 50% after announcing it raised over $31 million in funding from selling shares. But is the selloff justified? Cancer is the third leading cause of death in women. What’s more, ...
We have seen 26 institutional investors add shares of $CNTX stock to their portfolio, and 16 decrease their positions in their most recent quarter.
The latest price target for Context Therapeutics (NASDAQ:CNTX) was reported by D. Boral Capital on November 6, 2025. The analyst firm set a price target for $9.00 expecting CNTX to rise to within 12 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
HC Wainwright reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $5.00 ...
According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 31.1% and a 54.0% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results